Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20200105046010N95
IRCT20200105046010N95
Recruiting
未知

In-vivo Bioequivalence Study of Empagliflozin/Metformin 5/500 mg FC. Tablets of The Test Drug (JARINOMET® 5/500 mg Tab. Kharazmi Pharma, Iran) in Compared with The Reference Drug (SYNJARDI® 5/500 mg. Boehringer Ingelheim Germany) In Iranian Healthy Volunteers

Kharazmi Pharmacy0 sites24 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsThis study is performed on healthy volunteers and drug concentration in plasma is determined..

Overview

Phase
未知
Intervention
Not specified
Conditions
This study is performed on healthy volunteers and drug concentration in plasma is determined..
Sponsor
Kharazmi Pharmacy
Enrollment
24
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Kharazmi Pharmacy

Eligibility Criteria

Inclusion Criteria

  • •General Health (Liver, Heart, and Kidney)
  • •Body Mass Index (18\-28\)
  • •Informed consent
  • •Age (18\-55 years old)

Exclusion Criteria

  • •History of cardiovascular disease
  • •History of liver and kidney disease
  • •Alcohol and drug addiction
  • •History of allergy to Empagliflozin orMetoformin

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
In-vivo Bioequivalence Test of Empagliflozin-Metformin tablets with brand drug (Synjardy® 25/1000 mg, Boehringer Ingelheim, Germany)Bio equivalence test.
IRCT20200105046010N60Pars Darou Pharmaceutical Company24
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Empagliflozin tablets with brand drug (JARDIANCE® 25 mg, Boehringer Ingelheim , Germany)Bio equivalence test.
IRCT20200105046010N49Pars Darou Pharm. Co.24
Completed
Not Applicable
Bioequivalence study of Empagliflozin 5 mg/ Metformin 1000 mg film coated tablet manufactured by Modava Pharmaceutical Company
IRCT20130313012810N22Modava Pharmaceutical Company24
Not yet recruiting
Not Applicable
Bioequivalence study of Empagliflozin 12.5 mg+ Metformin 1000 mg in 24 healthy male under fasting conditions
IRCT20180620040164N13ACtover Pharmaceutical Co26
Recruiting
Not Applicable
Bioequivalence study of Empagliflozin 25 mg tablet in 24 healthy male under fasting conditionsBioequivalence investigation of the generic Actoverco. Empagliflozin 25 mg tablet with brand Jardiance 25 mg tablet Boehringer..
IRCT20180620040164N19Actover Pharmaceutical Co.24